Inactive Instrument

Analyst Reco. ARRD RESE Nasdaq

Equities

End-of-day quote Nasdaq Other stock markets
- ^USD	-

05/07	HC Wainwright Cuts Price Target on Arrowhead Pharmaceuticals to $60 From $90, Keeps Buy Rating	MT
25/06	Arrowhead Pharmaceuticals to Advance Investigational Medicine Plozasiran Into Late-stage Cardiovascular Study	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Cuts Price Target on Arrowhead Pharmaceuticals to $60 From $90, Keeps Buy Rating	05/07	MT
UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating	10/05	MT
B. Riley Adjusts Arrowhead Pharmaceuticals' PT to $55 From $50, Keeps Buy Rating	08/02	MT
UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $75 From $78, Maintains Buy Rating	07/02	MT
BofA Securities Initiates Arrowhead Pharmaceuticals at Buy Rating With $29 Price Target	04/12	MT
B. Riley Lowers Arrowhead Pharmaceuticals' Price Target to $50 From $60, Notes Higher Cash Burn; Keeps Buy Rating	04/12	MT
Morgan Stanley Cuts Price Target on Arrowhead Pharmaceuticals to $37 From $40, Maintains Equal-Weight Rating	30/11	MT
TD Cowen Starts Arrowhead Pharmaceuticals at Outperform	21/23/21	MT
Piper Sandler Adjusts Price Target on Arrowhead Pharmaceuticals to $59 From $52, Maintains Overweight Rating	02/23/02	MT
SVB Leerink Downgrades Arrowhead Pharmaceuticals to Market Perform From Outperform, Price Target is $40	12/23/12	MT
Goldman Sachs Adjusts Arrowhead Pharmaceuticals' Price Target to $73 From $65, Keeps Buy Rating	03/23/03	MT
Morgan Stanley Raises Price Target on Arrowhead Pharmaceuticals to $40 From $37, Maintains Equalweight Rating	03/23/03	MT
SVB Securities Upgrades Arrowhead Pharmaceuticals to Outperform From Market Perform, Raises PT to $35 From $21	12/23/12	MT
RBC Capital Adjusts Arrowhead Pharmaceuticals Price Target to $60 From $77, Maintains Outperform - Speculative Risk Rating	06/23/06	MT
Bernstein Initiates Arrowhead Pharmaceuticals at Market Perform With $27 Price Target	21/23/21	MT
B. Riley Lowers Arrowhead Pharmaceuticals' Price Target to $55 From $59, Keeps Buy Rating	08/23/08	MT
UBS Adjusts Arrowhead Pharmaceuticals' Price Target to $78 From $80, Maintains Buy Rating	07/23/07	MT
Baird Trims Price Target on Arrowhead Pharmaceuticals to $58 From $60, Maintains Outperform Rating	07/23/07	MT
RBC Capital Adjusts Price Target on Arrowhead Pharmaceuticals to $77 From $83 on Hepatitis B Virus Therapy Deprioritization, Keeps Outperform Rating	07/23/07	MT
Piper Sandler Adjusts Arrowhead Pharmaceuticals' Price Target to $52 From $55, Maintains Overweight Rating	07/23/07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. ARRD RESE Nasdaq

Equities

Analyst Reco.

Filters